Allen C. Gao

Academy of Medical Sciences — United Kingdom

Medicine · Health Sciences

62h-index11.3kcitations467works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(272), Cancer, Lipids, and Metabolism(67), PARP inhibition in cancer therapy(45), Estrogen and related hormone effects(44), Hormonal and reproductive studies(39)

Publications458 total

IGFBP3–SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer
Molecular Cancer Therapeutics·2025Open Access
A clinical-stage oncology compound selectively targets drug-resistant cancers
2025Open Access
P2.06.101 Neuroendocrine-Like Subtype or TMB-High Predicts Long-Term Survival Benefit From Sequential Thoracic Radiotherapy and ICI in ES-SCLC
Journal of Thoracic Oncology·2025
Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer
Cancers·2025Open Access
Integrated analysis of scRNA-seq and bulk RNA-seq data reveals the key targets of the combination of cisplatin and saikosaponin D in gastric cancer cells
Biochemical and Biophysical Research Communications·2025
Steroid Sulfatase Regulates Metabolic Reprogramming in Advanced Prostate Cancer
Cancers·2025· 1 citedOpen Access
Abstract 1720: IGFBP3 signaling promotes resistance to next-generation antiandrogens therapeutics in advanced prostate cancer
Cancer Research·2025
Abstract 560: Characterizing the role of TIAM1-Rac1 signaling in advanced prostate cancers
Cancer Research·2025
Abstract 4491: HSP70 leverages STUB1 to modulate N-Myc protein turnover in lethal prostate cancer
Cancer Research·2025
Abstract 1722: Targeting synaptotagmin 4 to overcome enzalutamide and abiraterone resistance in castration resistant prostate cancer
Cancer Research·2025
Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer
Oncogene·2025Open Access
IP26-14 THERAPEUTIC TARGETING OF ARHGEF2 -RAC1 SIGNALING FOR NEUROENDOCRINE PROSTATE CANCER
The Journal of Urology·2025
IP26-23 DEGRADATION OF N-MYC BY HSP70 INHIBITION ENHANCES THE EFFECT OF ALISERTIB IN ADVANCED PROSTATE CANCER
The Journal of Urology·2025
PD35-02 LX1 TARGETS ANDROGEN RECEPTOR VARIANTS AND AKR1C3 TO OVERCOME THERAPY RESISTANCE IN ADVANCED PROSTATE CANCER
The Journal of Urology·2025
MP32-06 HSP70 LEVERAGES STUB1 TO MODULATE N-MYC PROTEIN TURNOVER IN LETHAL PROSTATE CANCER
The Journal of Urology·2025
IP05-01 PLXND1 IS A POTENTIAL THERAPEUTIC TARGET AND PROGNOSTIC MARKER FOR NEUROENDOCRINE PROSTATE CANCER
The Journal of Urology·2025
Figure S5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Figure S3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Figure S1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
Figure S2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
2025Open Access
page 1 of 23Next →

Frequent Co-authors

Wei Lou(30), Christopher P. Evans(24), Nagalakshmi Nadiminty(16), Chengfei Liu(14), Joy C. Yang(10), Yezi Zhu(9), Soo Ok Lee(7), Cameron M. Armstrong(7), Ramakumar Tummala(6), Ralph W. deVere White(4), June X. Zou(4), Hsing-Jien Kung(4), Xinbin Chen(4), Donald L. Trump(4), Yan Dong(4), Clement Ip(4), Alan P. Lombard(4), Matthew B. Rettig(3), Martin Gleave(3), Jin‐Tang Dong(3)